Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19115016 | 0.77 | LMNA (0.33) | LMNASLC6A6CYP2C19BLM | |
| SCHEMBL2568445 | 0.74 | — | — | |
| SCHEMBL15226205 | 0.73 | CETP (0.38) | CA1CA2CA7CA13 | |
| SCHEMBL28254281 | 0.73 | EPHX1 (0.34) | CA1CA2CA7CA13 | |
| SCHEMBL1768683 | 0.71 | PMP22 (0.44) | BLM | |
| SCHEMBL1769476 | 0.71 | PMP22 (0.44) | BLM | |
| SCHEMBL443901 | 0.70 | RELA (0.40) | LMNASLC6A6CYP2C19BLMCA1 | |
| SCHEMBL1658730 | 0.70 | CA2 (0.45) | CA1CA2CA7CA13 | |
| SCHEMBL25787384 | 0.69 | — | — | |
| SCHEMBL6263448 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-110016020-B | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 赛克里翁治疗有限公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3660013-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-11207323-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11207323-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| CN-108912111-B | Compounds and pharmaceutical compositions | 赛克里翁治疗有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970243-A2 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2875007-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | Bristol-Myers Squibb Company (US) | 2015-05-27 | — | — | EP | disclosed |
| US-8987314-B2 | Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987314-B2 | Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140045811-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-02-13 | — | — | US | disclosed |
| US-20140045811-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-02-13 | — | — | US | disclosed |
| WO-2014015088-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | LMNA 3314/4885SLC6A6 4213/4885CYP2C19 1024/4885 |
| US-20140045811-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LIPE, CEL | LMNA 1733/4885SLC6A6 2345/4885CYP2C19 1591/4885 |
| US-11207323-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | LMNA 3314/4885SLC6A6 4213/4885CYP2C19 1024/4885 |
| US-20160031903-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | LMNA 3314/4885SLC6A6 4213/4885CYP2C19 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.